|
Official website
|
Add: date, authors 1-1. Removed parameters. Some additions/deletions were parameter name changes. | Use this bot. Report bugs. | Suggested by Spinixster | Category:Pharmaceutical companies of the United States | #UCB_Category 3/220
|
||
| (94 intermediate revisions by 57 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|U.S. healthcare company}} |
|||
'''Reata Pharmaceuticals, Inc.''' is a biopharmaceutical company based in [[Irving, Texas]]. Founded in 2002, Reata is currently developing oral anti-inflammatory drugs targeting [[Nrf2]], a master regulator of the antioxidant response in humans. Through its control of the body's production of [[antioxidants]], Nrf2 protects against a broad range of [[inflammation]] and [[oxidative stress]] related diseases, including [[renal disease]],<ref>{{cite journal |last1=Cachofeiro |first1=Victoria |last2=Goicochea |first2=Marian |last3=De Vinuesa |first3=Soledad García |last4=Oubiña |first4=Pilar |last5=Lahera |first5=Vicente |last6=Luño |first6=José |title=Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease |journal=Kidney International |volume=74 |pages=S4–9 |year=2008 |doi=10.1038/ki.2008.516}}</ref><ref>{{cite journal |last1=Sela |first1=S. |last2=Shurtz-Swirski |first2=R |last3=Cohen-Mazor |first3=M |last4=Mazor |first4=R |last5=Chezar |first5=J |last6=Shapiro |first6=G |last7=Hassan |first7=K |last8=Shkolnik |first8=G |last9=Geron |first9=R |title=Primed Peripheral Polymorphonuclear Leukocyte: A Culprit Underlying Chronic Low-Grade Inflammation and Systemic Oxidative Stress in Chronic Kidney Disease |journal=Journal of the American Society of Nephrology |volume=16 |issue=8 |pages=2431–8 |year=2005 |pmid=15987755 |doi=10.1681/ASN.2004110929}}</ref><ref>{{cite journal |last1=Vaziri |first1=Nosratola D |title=Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension |journal=Current Opinion in Nephrology and Hypertension |volume=13 |issue=1 |pages=93–9 |year=2004 |pmid=15090865 |doi=10.1097/00041552-200401000-00013}}</ref> [[cancer]],<ref>{{cite journal |last1=Klaunig |first1=JE |last2=Xu |first2=Y |last3=Isenberg |first3=JS |last4=Bachowski |first4=S |last5=Kolaja |first5=KL |last6=Jiang |first6=J |last7=Stevenson |first7=DE |last8=Walborg Jr |first8=EF |title=The role of oxidative stress in chemical carcinogenesis |journal=Environmental health perspectives |volume=106 Suppl 1 |pages=289–95 |year=1998 |pmid=9539021 |pmc=1533298}}</ref> [[cardiovascular disease]]s,<ref>{{cite journal |last1=Dhalla |first1=Naranjan |last2=Temsah |first2=Rana |last3=Netticadan |first3=Thomas |title=Role of oxidative stress in cardiovascular diseases. |journal=Journal of Hypertension |volume=18 |issue=6 |pages=655–73 |year=2000 |pmid=10872549 |doi=10.1097/00004872-200018060-00002}}</ref><ref>{{cite journal |last1=Madamanchi |first1=N. R. |title=Oxidative Stress and Vascular Disease |journal=Arteriosclerosis, Thrombosis, and Vascular Biology |year=2004 |doi=10.1161/01.ATV.0000150649.39934.13}}</ref> and neurological diseases (eg: [[multiple sclerosis]],<ref>{{cite journal |last1=Offen |first1=Daniel |last2=Gilgun-Sherki |first2=Yossi |last3=Melamed |first3=Eldad |title=The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy |journal=Journal of Neurology |volume=251 |issue=3 |pages=261–8 |year=2004 |pmid=15015004 |doi=10.1007/s00415-004-0348-9}}</ref><ref>{{cite journal |last1=Syburra |first1=C |last2=Passi |first2=S |title=Oxidative stress in patients with multiple sclerosis |journal=Ukrainskii biokhimicheskii zhurnal |volume=71 |issue=3 |pages=112–5 |year=1999 |pmid=10609336}}</ref> [[amyotrophic lateral sclerosis]],<ref>{{cite journal |last1=Simpson |first1=Ericka P. |last2=Yen |first2=Albert A. |last3=Appel |first3=Stanley H. |title=Oxidative Stress: a common denominator in the pathogenesis of amyotrophic lateral sclerosis |journal=Current Opinion in Rheumatology |volume=15 |issue=6 |pages=730–6 |year=2003 |pmid=14569202 |doi=10.1097/00002281-200311000-00008}}</ref><ref>{{cite journal |last1=Ferrante |first1=Robert J. |last2=Browne |first2=Susan E. |last3=Shinobu |first3=Leslie A. |last4=Bowling |first4=Allen C. |last5=Baik |first5=M. Jay |last6=MacGarvey |first6=Usha |last7=Kowall |first7=Neil W. |last8=Brown |first8=Robert H. |last9=Beal |first9=M. Flint |title=Evidence of Increased Oxidative Damage in Both Sporadic and Familial Amyotrophic Lateral Sclerosis |journal=Journal of Neurochemistry |volume=69 |issue=5 |pages=2064–74 |year=2002 |pmid=9349552 |doi=10.1046/j.1471-4159.1997.69052064.x}}</ref> [[alzheimer's disease]].<ref>{{cite journal |last1=Markesbery |first1=W |title=Oxidative Stress Hypothesis in Alzheimer's Disease |journal=Free Radical Biology and Medicine |volume=23 |issue=1 |pages=134–47 |year=1997 |pmid=9165306 |doi=10.1016/S0891-5849(96)00629-6}}</ref> |
|||
{{Infobox company |
|||
| name = Reata Pharmaceuticals, Inc. |
|||
| industry = [[Biotechnology]] |
|||
| traded_as = {{NASDAQ was|RETA}} |
|||
| fate = Acquired by [[Biogen]] |
|||
| revenue = {{down}} US $26.52 million {{small|(2019)}}<br/> |
|||
{{up}} US $53.59 million {{small|(2018)}}<ref>{{Cite web|url=https://www.marketwatch.com/investing/stock/reta/financials|title = RETA | Reata Pharmaceuticals Inc. Cl a Annual Income Statement}}</ref> |
|||
| owner = {{ubl|[[Biogen]] {{smaller|(2023–present)}}}} |
|||
| website = {{URL|https://www.reatapharma.com}} |
|||
}} |
|||
'''Reata Pharmaceuticals, Inc.''' is a pharmaceutical company based in [[Plano, Texas]]. Founded in 2002, it is primarily focused on investigating experimental oral [[antioxidative]] and [[anti-inflammatory]] drugs,<ref name="OurStory">{{cite web|title=Our Story|url=http://reatapharma.com/about-us/our-story/|website=Reata Pharmaceuticals|access-date=5 August 2016}}</ref> which dually activate the antioxidative transcription factor [[Nrf2]] and inhibit the pro-inflammatory transcription factor [[NF-κB]].<ref>{{Cite journal|title = New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress|vauthors=Sporn MB, Liby KT, Yore MM |date = 2011|journal = J Nat Prod|doi = 10.1021/np100826q|pmid = 21309592|volume = 74|issue=3 |pages = 537–45|pmc=3064114|display-authors=etal}}</ref> |
|||
In July 2023, it was announced Reata had been acquired by the [[Cambridge, Massachusetts]]-headquartered [[Multinational corporation|multinational]] [[biotechnology]] company, [[Biogen]] for nearly $6.5 billion.<ref>{{Cite news |last1=Mishra |first1=Manas |last2=Satija |first2=Bhanvi |last3=Satija |first3=Bhanvi |date=2023-07-28 |title=Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio |language=en |work=Reuters |url=https://www.reuters.com/markets/deals/biogen-buy-reata-65-bln-bulk-up-rare-disease-portfolio-2023-07-28/ |access-date=2023-07-28}}</ref> The purchase was completed on September 26 and Reata stock was delisted from the Nasdaq.<ref>{{Cite web|url=https://finance.yahoo.com/news/biogen-completes-acquisition-reata-pharmaceuticals-125900936.html|title=Biogen Completes Acquisition of Reata Pharmaceuticals|work=Yahoo! Finance|date=26 September 2023 |access-date=2023-10-05|language=en-US}}</ref> |
|||
==Bardoxolone Methyl== |
|||
Reata's lead program, [[bardoxolone methyl]], is the first Antioxidant Inflammation Modulator (AIM) to enter [[clinical trial]]s. The drug has been shown to significantly increase [[Renal function|estimated glomerular filtration rate (GFR)]], and improve several other markers of kidney function in patients with [[chronic kidney disease]] (CKD).<ref>{{cite press release |title=Reata to Present at Jefferies 2010 Global Life Sciences Conference |publisher=Reata Pharmaceuticals |date=June 9, 2010 |url=http://www.reatapharma.com/news_detail.asp?id=60 |accessdate=October 28, 2010}}</ref> Bardoxolone methyl has been advanced to late-stage, pivotal clinical trials in patients with chronic kidney disease and [[type 2 diabetes]]. |
|||
== Pipeline == |
|||
Data from three clinical studies of bardoxolone methyl have demonstrated that the drug is: |
|||
The antioxidative and anti-inflammatory compounds [[bardoxolone methyl]] and [[RTA 408]] are the lead clinical development compounds in Reata’s portfolio. |
|||
* Producing a significant increase in estimated glomerular filtration rate (eGFR), which is consistent in magnitude and in the high degree of patient response. |
|||
* Improving CKD stage (ie: from Stage 4 to Stage 3) in the majority of patients. |
|||
* Improving multiple additional measures of renal function, such as [[blood urea nitrogen]] (BUN), serum phosphorus, [[uric acid]], and [[magnesium]]. |
|||
* Well-tolerated. |
|||
* Suitable for once-daily dosing. |
|||
* Targeting Nrf2 pathway and supporting an anti-inflammatory mechanism.<ref>http://www.reatapharma.com/pip_rta402.asp#clinical</ref> |
|||
=== |
=== Bardoxolone Methyl === |
||
[[Bardoxolone methyl]] was one of the first of the class of synthetic triterpenoids to be studied in the clinic. It has been evaluated in Phase 1 studies for [[cancer]],<ref>{{Cite journal|url= |title = A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas|vauthors=Hong DS, Kurzrock R, Supko JG |date = 2012|journal = Clin Cancer Res|doi = 10.1158/1078-0432.CCR-11-2703|pmid = 22634319|volume = 18|issue = 12|pages = 3396–406|display-authors=etal|pmc=4494099}}</ref> Phase 2 and 3 studies for [[chronic kidney disease]] (CKD) associated with [[Diabetes mellitus type 2|type 2 diabetes]],<ref>{{Cite journal|title = Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes|vauthors=Pergola PE, Raskin P, Toto RD |date = 2011|journal = N Engl J Med|doi = 10.1056/NEJMoa1105351|pmid = 21699484|pages = 327–36|volume = 365|issue = 4|display-authors=etal|doi-access = free}}</ref><ref>{{Cite journal|title = Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease|vauthors=de Zeeuw D, Akizawa T, Audhya P |date = 2013|journal = N Engl J Med|doi = 10.1056/NEJMoa1306033|pmid = 24206459|pages = 2492–503|volume = 369|issue = 26|display-authors=etal|pmc=4496027}}</ref> and is currently being evaluated in a Phase 2 study for [[pulmonary hypertension|pulmonary arterial hypertension]].<ref>{{Cite news|url = http://pulmonaryhypertensionnews.com/2014/06/30/reata-begins-enrollment-pah-lariat-phase-2-study-examining-bardoxolone-methyl-treating-pulmonary-arterial-hypertension/|title = Reata Begins Enrollment For PAH – LARIAT Phase 2 Study Examining Bardoxolone Methyl for Treating Pulmonary Arterial Hypertension|access-date = 6 October 2014}}</ref><ref>{{Cite news|url = http://clinicaltrials.gov/ct2/show/NCT02036970?term=bardoxolone&rank=4|title = Bardoxolone Methyl Evaluation in Patients With Pulmonary Arterial Hypertension (PAH) (LARIAT)|access-date = 6 October 2014}}</ref><ref>{{Cite news|url = http://www.fiercebiotech.com/story/after-taste-disaster-reata-plans-comeback-bardoxolone/2014-07-09|title = After a taste of disaster, Reata plans a comeback for bardoxolone|last = Carroll|first = John|date = 6 October 2014}}</ref> |
|||
Chronic Kidney Disease (CKD) is a common complication of [[diabetes]] and [[hypertension]] that affects over 26 million Americans.<ref>{{cite journal |author1=Centers for Disease Control and Prevention |title=Prevalence of chronic kidney disease and associated risk factors—United States, 1999–2004 |journal=Morbidity and Mortality Weekly Report |volume=56 |issue=8 |pages=161–5 |year=2007 |pmid=17332726 |url=http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5608a2.htm}}</ref> It is a progressive condition that ultimately leads to End Stage Renal Disease (ESRD) and the need for [[dialysis]] or transplant, and is associated with dramatic increase in the risk of cardiovascular disease.<ref>{{cite journal |last1=Anavekar |first1=Nagesh S. |last2=Pfeffer |first2=Marc A. |title=Cardiovascular risk in chronic kidney disease |journal=Kidney International |volume=66 |pages=S11–5 |year=2004 |pmid=9573568 |doi=10.1111/j.1523-1755.2004.09203.x}}</ref> Current standard of care can slow the progression of the disease,<ref>{{cite web |title=Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in CKD |publisher=[[National Kidney Foundation]] |url=http://www.kidney.org/professionals/kdoqi/guidelines_bp/guide_11.htm}} in {{cite journal |author1=Kidney Disease Outcomes Quality Initiative (K/DOQI) |title=K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease |journal=American journal of kidney diseases |volume=43 |issue=5 Suppl 1 |pages=S1–290 |year=2004 |pmid=15114537}}</ref> but no treatments are currently available to stop it. Due to the high prevalence of the condition, and absence of disease modifying therapy, CKD represents an area of significant unmet medical need. |
|||
== |
=== RTA 408 === |
||
'''[[Omaveloxolone]]''' (RTA 408) is a second generation member of the synthetic oleanane triterpenoid compounds and currently in clinical development. Preclinical studies have demonstrated that RTA 408 possesses antioxidative and anti-inflammatory activities,<ref>{{Cite journal|title = Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin.|vauthors=Reisman SA, Lee CY, Meyer CJ |date = 2014|journal = Arch Dermatol Res|doi = 10.1007/s00403-013-1433-7|pmid = 24362512|pages = 447–57|volume = 306|issue = 5|s2cid=25733020 |display-authors=etal}}</ref><ref>{{Cite journal|title = Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis.|vauthors=Reisman SA, Lee CY, Meyer CJ |date = 2014|journal = Radiat Res|doi = 10.1667/RR13578.1|pmid = 24720753|pages = 512–20|volume = 181|issue = 5|bibcode=2014RadR..181..512R |s2cid=23906747 |display-authors=etal|doi-access = free}}</ref> as well as the potential to improve mitochondrial bioenergetics.<ref>{{Cite journal|title = Neuroprotective effect of Nrf2/ARE Activators, CDDO-ethylamide and CDDO-trifluoroethylamide in a Mouse Model of Amyotrophic Lateral Sclerosis|vauthors=Neymotin A, Calingasan NY, Wille E |date = 2011|journal = Free Radic Biol Med|doi = 10.1016/j.freeradbiomed.2011.03.027|pmid = 21457778|pages = 88–96|volume = 51|issue=1 |pmc=3109235|display-authors=etal}}</ref> Because of the broad applicability of such effects across many diseases, RTA 408 is currently under clinical investigation in several Phase 2 clinical studies including [[immunooncology]],<ref>{{Cite web|url = http://clinicaltrials.gov/ct2/show/NCT02029729?term=reata&recr=Open&rank=2|title = RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma)|access-date = 6 October 2014}}</ref> [[Corneal endothelium|corneal endothelial cell]] loss associated with cataract surgery<ref>{{Cite web|url = https://clinicaltrials.gov/ct2/show/NCT02128113|title = RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD|date = April 15, 2015}}</ref> [[Friedreich’s ataxia]],<ref>{{Cite web|url = http://clinicaltrials.gov/ct2/show/NCT02255435?term=reata&recr=Open&rank=4|title = RTA 408 Capsules in Patients With Friedreich's Ataxia (MOXIe)|access-date = 6 October 2014}}</ref> and [[mitochondrial myopathies]].<ref>{{Cite web|url = http://clinicaltrials.gov/ct2/show/NCT02255422?term=reata&recr=Open&rank=5|title = RTA 408 Capsules in Patients With Mitochondrial Myopathy (MOTOR)|access-date = 6 October 2014}}</ref><ref>{{Cite web|url = http://www.marketwatch.com/story/reata-announces-the-initiation-of-phase-2-studies-examining-rta-408-for-the-treatment-of-friedreichs-ataxia-and-mitochondrial-myopathies-2014-09-30|title = Reata Announces the Initiation of Phase 2 Studies Examining RTA 408 for the Treatment of Friedreich's Ataxia and Mitochondrial Myopathies|access-date = 6 October 2014}}</ref> |
|||
Reata is developing a series of other Antioxidant Inflammation Modulators (AIMs) with activity against a variety of intractable diseases. These unique drugs help to restore the balance between pro-oxidant and antioxidant signaling molecules within the cell by mimicking the body's own natural regulators of inflammation.<ref>{{cite press release |title=Two Studies Support AIMs Development |publisher=Reata Pharmaceuticals |date=July 8, 2009 |url=http://www.dddmag.com/news-Two-Studies-Support-AIMs-Development-070809.aspx |accessdate=October 28, 2010}}</ref><ref>http://www.natap.org/2009/HIV/062109_03.htm</ref> By increasing the production of enzymes that maintain the antioxidant buffering system within the cell, they prevent harmful inflammation and the associated oxidative stress and organ/[[Deoxyribonucleic acid|DNA]] damage caused by high concentrations of oxygen and nitrogen radicals. Also, by activating enzymes that maintain the antioxidant buffering system, they increase the body's ability to protect against tissue damage from toxic insults, [[Chronic (medicine)|chronic]] health problems, and [[aging]]. |
|||
== |
=== Others === |
||
Reata is also actively engaged in the discovery of small molecule disease-modifying drugs that function by stabilizing the normal three-dimensional structure of target proteins or generally enhancing the folding environment of the cell. Defects in protein folding underlie a large number of genetic diseases including certain forms of [[cancer]], familial [[Alzheimer's disease]], and [[cystic fibrosis]]. [[Protein folding]] defects are also believed to play important roles in the development of non-inherited forms of many of these diseases. |
|||
'''January 7, 2010''' - Reata announced that they entered into a [[licensing agreement]] with [[Kyowa Hakko Kirin|Kyowa Hakko Kirin Co., Ltd]]. The agreement provided Kyowa Hakko Kirin with the exclusive rights to develop and commercialize bardoxolone methyl for CKD and related indications in [[Japan]], [[China]], [[Taiwan]], [[Korea]], and other select [[Southeast Asia]]n countries. In return, Reata is eligible to receive up to $272 million in up-front fees and milestone payments, in addition to escalating double-digit [[royalties]] from sales in the licensed territories.<ref>http://www.biospace.com/news_story.aspx?NewsEntityId=167221</ref><ref>http://www.fiercebiotech.com/special-reports/emerging-drug-developer-reata-pharmaceuticals</ref><ref>http://www.medicalnewstoday.com/articles/175571.php</ref> |
|||
== Partnerships == |
|||
'''September 23, 2010''' - [[Abbott]] and Reata announced that they entered into a collaboration agreement to develop and commercialize bardoxolone methyl. Under the agreement, Reata granted Abbott exclusive rights to develop and commercialize bardoxolone methyl outside the U.S., excluding Asian markets outlined in the January 7th agreement with Kyowa Hakko Kirin. In exchange, Reata received upfront and near-term cash payments of $450 million for the licensing rights and a minority equity stake in the company. Additionally, Reata will receive milestone payments upon completion of certain development and approval objectives for bardoxolone in the licensed territories.<ref>http://www.biospace.com/news_story.aspx?NewsEntityId=195321</ref><ref>http://www.marketwatch.com/story/abbott-and-reata-pharmaceuticals-announce-agreement-to-develop-and-commercialize-bardoxolone-methyl-for-chronic-kidney-disease-outside-the-us-2010-09-23</ref><ref>http://www.bizjournals.com/dallas/stories/2010/10/04/story4.html</ref> |
|||
Reata has a [[licensing agreement]] with [[Kyowa Hakko Kirin]] for development and commercialization of [[bardoxolone methyl]] for CKD and related indications in [[Japan]], [[China]], [[Taiwan]], [[Korea]], and other select Southeast Asian countries.<ref>{{Cite news|url = https://www.bloomberg.com/apps/news?pid=newsarchive&sid=a43aaS3QleNo|title = Reata Pharmaceuticals Licenses Chronic Kidney Disease Drug|access-date = 6 October 2014}}</ref> |
|||
Reata also has a licensing agreement with [[Abbvie]] for development and commercialization of bardoxolone methyl outside the U.S., excluding Asian markets defined in the agreement with [[Kyowa Hakko Kirin]].<ref>{{Cite news|url = http://www.fiercebiotech.com/press-releases/abbott-and-reata-pharmaceuticals-announce-agreement-develop-and-commercialize-bardoxo|title = Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl|access-date = 6 October 2014}}</ref> [[Abbvie]] and Reata also have a second agreement for development of the second generation portfolio of synthetic oleanane triterpenoid compounds, including RTA 408, as well as other Nrf2 activators.<ref>{{Cite news|url = http://www.fiercebiotech.com/story/abbott-bets-400m-mega-blockbuster-future-reata-program/2011-12-12|title = Updated: Abbott bets $400M on mega-blockbuster future for Reata program|last = Carroll|first = John|access-date = 6 October 2014}}</ref> |
|||
== References == |
== References == |
||
| Line 27: | Line 35: | ||
==External links== |
==External links== |
||
* |
* {{official|https://www.reatapharma.com}} |
||
{{Finance links |
|||
| name = Reata Pharmaceuticals |
|||
| symbol = RETA |
|||
| reuters = RETA.O |
|||
| bloomberg = RETA:US |
|||
| sec_cik = RETA |
|||
| yahoo = RETA |
|||
| google = RETA |
|||
}} |
|||
{{authority control}} |
|||
[[Category:Pharmaceutical companies of the United States]] |
[[Category:Pharmaceutical companies of the United States]] |
||
[[Category: |
[[Category:Pharmaceutical companies established in 2002]] |
||
[[Category:Companies based in Plano, Texas]] |
|||
[[Category:Health care companies based in Texas]] |
|||
[[Category:Companies formerly listed on the Nasdaq]] |
|||
[[Category:2016 initial public offerings]] |
|||
[[Category:2023 mergers and acquisitions]] |
|||
| Nasdaq: RETA | |
| Industry | Biotechnology |
| Founded | 1 January 2002  |
| Fate | Acquired by Biogen |
| Revenue |  US $26.52 million (2019) US $53.59 million (2018)[1] |
| Owner |
|
| Website | www |
Reata Pharmaceuticals, Inc. is a pharmaceutical company based in Plano, Texas. Founded in 2002, it is primarily focused on investigating experimental oral antioxidative and anti-inflammatory drugs,[2] which dually activate the antioxidative transcription factor Nrf2 and inhibit the pro-inflammatory transcription factor NF-κB.[3]
In July 2023, it was announced Reata had been acquired by the Cambridge, Massachusetts-headquartered multinational biotechnology company, Biogen for nearly $6.5 billion.[4] The purchase was completed on September 26 and Reata stock was delisted from the Nasdaq.[5]
The antioxidative and anti-inflammatory compounds bardoxolone methyl and RTA 408 are the lead clinical development compounds in Reata’s portfolio.
Bardoxolone methyl was one of the first of the class of synthetic triterpenoids to be studied in the clinic. It has been evaluated in Phase 1 studies for cancer,[6] Phase 2 and 3 studies for chronic kidney disease (CKD) associated with type 2 diabetes,[7][8] and is currently being evaluated in a Phase 2 study for pulmonary arterial hypertension.[9][10][11]
Omaveloxolone (RTA 408) is a second generation member of the synthetic oleanane triterpenoid compounds and currently in clinical development. Preclinical studies have demonstrated that RTA 408 possesses antioxidative and anti-inflammatory activities,[12][13] as well as the potential to improve mitochondrial bioenergetics.[14] Because of the broad applicability of such effects across many diseases, RTA 408 is currently under clinical investigation in several Phase 2 clinical studies including immunooncology,[15] corneal endothelial cell loss associated with cataract surgery[16] Friedreich’s ataxia,[17] and mitochondrial myopathies.[18][19]
Reata is also actively engaged in the discovery of small molecule disease-modifying drugs that function by stabilizing the normal three-dimensional structure of target proteins or generally enhancing the folding environment of the cell. Defects in protein folding underlie a large number of genetic diseases including certain forms of cancer, familial Alzheimer's disease, and cystic fibrosis. Protein folding defects are also believed to play important roles in the development of non-inherited forms of many of these diseases.
Reata has a licensing agreement with Kyowa Hakko Kirin for development and commercialization of bardoxolone methyl for CKD and related indications in Japan, China, Taiwan, Korea, and other select Southeast Asian countries.[20]
Reata also has a licensing agreement with Abbvie for development and commercialization of bardoxolone methyl outside the U.S., excluding Asian markets defined in the agreement with Kyowa Hakko Kirin.[21] Abbvie and Reata also have a second agreement for development of the second generation portfolio of synthetic oleanane triterpenoid compounds, including RTA 408, as well as other Nrf2 activators.[22]
